ADAR1 Capital Management »

Mineralys Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Mineralys Therapeutics (MLYS) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Mineralys Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Mineralys Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Mineralys Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $8.8M 729k 12.11
2024-06-30 $297k 25k 11.70
2024-03-31 $310k 24k 12.91

More positions owned by ADAR1 Capital Management

Cytokinetics Com New (CYTK)
Protagonist Therapeutics (PTGX)
Bridgebio Pharma (BBIO)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Immunovant (IMVT)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Ascendis Pharma A/s Sponsored Adr (ASND)
Zura Bio Class A Ord Shs (ZURA)
Zai Lab Adr (ZLAB)
Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Aa Mission Acquisition Corp Ord Shs Cl A (AAM)
Mineralys Therapeutics (MLYS)
Syndax Pharmaceuticals (SNDX)

View all positions for ADAR1 Capital Management

Top funds holding Mineralys Therapeutics

Catalys Pacific
Samsara BioCapital
RA Capital Management
TCG Crossover Management
BlackRock
Sr One Capital Management
OrbiMed Advisors
Franklin Resources
Adams Street Partners
Laurion Capital Management
Vanguard Group
Jennison Associates
Caligan Partners
American Century Companies
ADAR1 Capital Management

View all funds holding Mineralys Therapeutics